TFD-100(TFD-100) - 药物靶点：galectin-3_在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

合成多肽

别名

靶点

galectin-3

作用方式

抑制剂

作用机制

galectin-3抑制剂(半乳糖凝集素3抑制剂)

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症-

原研机构

University of Maryland Baltimore County

在研机构

GlycoMantra, Inc.

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 TFD-100 相关的临床结果

登录后查看更多信息

100 项与 TFD-100 相关的转化医学

登录后查看更多信息

100 项与 TFD-100 相关的专利（医药）

登录后查看更多信息

1

项与 TFD-100 相关的文献（医药）

2013-03-26·Proceedings of the National Academy of Sciences1区 · 综合性期刊

Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis

1区 · 综合性期刊

Article

作者: Kaptan, Engin ; Ahmed, Hafiz ; Kalvakolanu, Dhananjaya V. ; Thompson, Keyata ; Davila, Eduardo ; Kaczanowska, Sabina ; Martin, Stuart S. ; Bandyopadhyaya, Gargi ; Guha, Prasun ; Vasta, Gerardo R.

Cancer metastasis and immune suppression are critical issues in cancer therapy. Here, we show that a β-galactoside–binding lectin [galectin-3 (gal3)] that recognizes the Thomsen-Friedenreich disaccharide (TFD, Galβ1,3GalNAc) present on the surface of most cancer cells is involved in promoting angiogenesis, tumor-endothelial cell adhesion, and metastasis of prostate cancer cells, as well as evading immune surveillance through killing of activated T cells. To block gal3-mediated interactions, we purified a glycopeptide from cod (designated TFD 100 ) that binds gal3 with picomolar affinity. TFD 100 blocks gal3-mediated angiogenesis, tumor-endothelial cell interactions, and metastasis of prostate cancer cells in mice at nanomolar levels. Moreover, apoptosis of activated T cells induced by either recombinant gal3 or prostate cancer patient serum-associated gal3 was inhibited at nanomolar concentration of TFD 100 . Because the gal3–TFD interaction is a key factor driving metastasis in most epithelial cancers, this high-affinity TFD 100 should be a promising antimetastatic agent for the treatment of various cancers, including prostate adenocarcinoma.

100 项与 TFD-100 相关的药物交易

登录后查看更多信息